Sweden’s Meda Buying U.S. Respiratory Specialist Acton For Aerospan
This article was originally published in The Pink Sheet Daily
Swedish specialty pharma Meda is buying Acton Pharmaceuticals to get the privately held group’s Aerospan inhaler for treating asthma, approved by FDA in September 2012 and poised – pending satisfaction of further manufacturing requirements – for a U.S. launch in early 2014.
You may also be interested in...
Evotec’s multimodality approach to drug discovery landed the biotech two new discovery collaborations this week, underscoring its emphasis on patient-driven data.
Novo Nordisk and Evotec will identify and develop novel drugs for treating chronic kidney disease, using datasets of CKD patients provided by the Danish group and from other sources.
Sanofi is paying for $3.68bn cash for Principia to get the US biotech’s drug development platform and nascent pipeline, including a brain-penetrant BTK inhibitor in Phase III for multiple sclerosis.